Page last updated: 2024-09-05

dabigatran and per977

dabigatran has been researched along with per977 in 18 studies

Compound Research Comparison

Studies (dabigatran)	Trials (dabigatran)	Recent Studies (post-2010) (dabigatran)	Studies (per977)	Trials (per977)	Recent Studies (post-2010) (per977)
3,887	261	3,490	46	3	45

Research

Studies (18)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	16 (88.89)	24.3611
2020's	2 (11.11)	2.80

Authors

Authors	Studies
Ansell, J; Bakhru, S; Costin, J; Laulicht, B; Steiner, S	1
Cuker, A; Siegal, D	1
Agewall, S; Atar, D; Drexel, H; Husted, SE; Kaski, JC; Kjeldsen, K; Koller, L; Lewis, BS; Lip, GYH; Morais, J; Niessner, A; Storey, RF; Tamargo, J; Torp-Pedersen, C; Verheugt, FWA; Wassmann, S	1
Ansell, JE	1
Fanikos, J; Smythe, MA; Trujillo, T	1
Hussain, SS; Mukherjee, D; Tyroch, AH	1
Kaminskas, E; Reiffel, JA; Reilly, P; Sager, P; Sarich, T; Seltzer, J; Weitz, JI	1
Antman, EM; Giugliano, RP; Ruff, CT	1
Fanikos, J; Huisman, MV	2
Levy, JH	1
Bhagirath, VC; Eikelboom, JW; Monagle, S; Ng, KH	1
Desborough, MJ; Shapiro, S; Zhang, XY	1
Gkiatas, I; Korompilias, AV; Kostas-Agnantis, I; Papadopoulos, DV; Tsantes, AG; Ziara, P	1
Fischer, AM; Godier, A; Martin, AC; Mauge, L; Smadja, DM	1
Ageno, W; Agnelli, G; Chan, NC; De Caterina, R; Diener, HC; Hylek, E; Lip, GYH; Raskob, GE; Siegal, DM; Verheugt, FWA; Weitz, JI	1
Bari, N; Ho, JPK; Riffat, F	1
Ansell, J; Bakhru, S; Freedman, D; Laulicht, BE; Tracey, G; Villano, S	1

Reviews

15 review(s) available for dabigatran and per977

Article	Year
Reversal agents in development for the new oral anticoagulants. Postgraduate medicine, 2014, Volume: 126, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Benzimidazoles; beta-Alanine; Blood Coagulation Factors; Clinical Trials, Phase III as Topic; Dabigatran; Factor Xa; Factor Xa Inhibitors; Humans; Piperazines; Recombinant Proteins; Thromboembolism	2014
Monitoring and reversal of direct oral anticoagulants. Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Factors; Blood Coagulation Tests; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostasis; Humans; Partial Thromboplastin Time; Piperazines; Prothrombin; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Thrombin Time	2015
Reversing the Effect of Oral Anticoagulant Drugs: Established and Newer Options. American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016, Volume: 16, Issue:3 Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antifibrinolytic Agents; Antithrombins; Arginine; Blood Coagulation Disorders; Blood Coagulation Factors; Coagulants; Combined Modality Therapy; Dabigatran; Drugs, Investigational; Enoxaparin; Factor Xa; Fibrinolytic Agents; Humans; Piperazines; Practice Guidelines as Topic; Recombinant Proteins; Vitamin K	2016
Reversal agents for use with direct and indirect anticoagulants. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2016, May-15, Volume: 73, Issue:10 Suppl 2 Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Recombinant Proteins	2016
Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs). Cardiovascular & hematological agents in medicinal chemistry, 2017, Volume: 14, Issue:2 Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Anticoagulants; Antifibrinolytic Agents; Arginine; Blood Coagulation; Blood Coagulation Factors; Cardiovascular Diseases; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Models, Molecular; Piperazines; Recombinant Proteins	2017
NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank. American heart journal, 2016, Volume: 177 Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Atrial Fibrillation; Congresses as Topic; Dabigatran; Drug Monitoring; Factor Xa; Factor Xa Inhibitors; Humans; Partial Thromboplastin Time; Piperazines; Product Surveillance, Postmarketing; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thiazoles; Thrombin Time; Venous Thromboembolism	2016
Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents. Circulation, 2016, Jul-19, Volume: 134, Issue:3 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antithrombins; Arginine; Blood Coagulation Factors; Dabigatran; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Plasma; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles	2016
Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols. The American journal of medicine, 2016, Volume: 129, Issue:11S Topics: Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Clinical Protocols; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban	2016
Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. The American journal of medicine, 2016, Volume: 129, Issue:11S Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Dabigatran; Deprescriptions; Emergencies; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Piperazines; Prothrombin Time; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative	2016
Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols. The American journal of emergency medicine, 2016, Volume: 34, Issue:11S Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Clinical Protocols; Dabigatran; Emergency Treatment; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hospitals; Humans; Patient Selection; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Surgical Procedures, Operative; Thiazoles	2016
Clinical implications of reversal agents for direct oral anticoagulants. Future cardiology, 2017, Volume: 13, Issue:2 Topics: Antibodies, Monoclonal, Humanized; Anticoagulants; Antithrombins; Arginine; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism	2017
Reversal of direct oral anticoagulants. British journal of hospital medicine (London, England : 2005), 2017, Mar-02, Volume: 78, Issue:3 Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Coagulants; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Humans; Intracranial Hemorrhages; Male; Partial Thromboplastin Time; Piperazines; Prothrombin Time; Recombinant Proteins; Thrombin Time	2017
The role of new oral anticoagulants in orthopaedics: an update of recent evidence. European journal of orthopaedic surgery & traumatology : orthopedie traumatologie, 2017, Volume: 27, Issue:5 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Blood Coagulation Tests; Dabigatran; Factor Xa; Hemorrhage; Humans; Orthopedic Procedures; Piperazines; Practice Guidelines as Topic; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Rivaroxaban; Thiazoles; Venous Thromboembolism	2017
[State of the art: Direct oral anticoagulants and transfusion]. Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2017, Volume: 24, Issue:3 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Antidotes; Antithrombins; Arginine; Blood Coagulation Factors; Blood Transfusion; Dabigatran; Factor Xa; Factor Xa Inhibitors; Hemorrhage; Hemostatics; Humans; Piperazines; Pyrazoles; Pyridones; Recombinant Proteins; Rivaroxaban; Stroke; Thrombophilia	2017
The Non-Vitamin K Antagonist Oral Anticoagulants in Heart Disease: Section V-Special Situations. Thrombosis and haemostasis, 2019, Volume: 119, Issue:1 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Arginine; Atrial Fibrillation; Benzamides; Biomarkers; Blood Coagulation; Clinical Trials as Topic; Dabigatran; Drug Administration Schedule; Factor Xa; Heart Diseases; Humans; Piperazines; Pyrazoles; Pyridines; Pyridones; Recombinant Proteins; Risk; Rivaroxaban; Stroke; Thiazoles; Thrombin; Venous Thromboembolism; Vitamin K; Warfarin	2019

Trials

1 trial(s) available for dabigatran and per977

Article	Year
Ciraparantag reverses the anticoagulant activity of apixaban and rivaroxaban in healthy elderly subjects. European heart journal, 2022, Mar-07, Volume: 43, Issue:10 Topics: Administration, Oral; Adult; Aged; Anticoagulants; Arginine; Dabigatran; Healthy Volunteers; Humans; Middle Aged; Piperazines; Pyrazoles; Pyridones; Rivaroxaban	2022

Other Studies

2 other study(ies) available for dabigatran and per977

Article	Year
Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharm European heart journal, 2017, 06-07, Volume: 38, Issue:22 Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Arginine; Consensus; Dabigatran; Evidence-Based Medicine; Factor Xa; Forecasting; Hemorrhage; Humans; Piperazines; Recombinant Proteins; Risk Factors; Thrombosis; Vitamin K	2017
Management of epistaxis in patients on novel oral anticoagulation therapy. The Journal of laryngology and otology, 2020, Volume: 134, Issue:4 Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Awareness; Dabigatran; Epistaxis; Factor Xa; Factor Xa Inhibitors; First Aid; Humans; Male; Piperazines; Prevalence; Recombinant Proteins; Rivaroxaban; Severity of Illness Index	2020

Article

Year

Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management-a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharm

European heart journal, 2017, 06-07, Volume: 38, Issue:22

Topics: Administration, Oral; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Arginine; Consensus; Dabigatran; Evidence-Based Medicine; Factor Xa; Forecasting; Hemorrhage; Humans; Piperazines; Recombinant Proteins; Risk Factors; Thrombosis; Vitamin K

2017

Management of epistaxis in patients on novel oral anticoagulation therapy.

The Journal of laryngology and otology, 2020, Volume: 134, Issue:4

Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Antidotes; Antithrombins; Arginine; Awareness; Dabigatran; Epistaxis; Factor Xa; Factor Xa Inhibitors; First Aid; Humans; Male; Piperazines; Prevalence; Recombinant Proteins; Rivaroxaban; Severity of Illness Index

2020